STOCK TITAN

Gracell Biotechnologies Inc - GRCL STOCK NEWS

Welcome to our dedicated news page for Gracell Biotechnologies (Ticker: GRCL), a resource for investors and traders seeking the latest updates and insights on Gracell Biotechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gracell Biotechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gracell Biotechnologies's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.31%
Tags
-
Rhea-AI Summary
Gracell Biotechnologies Inc. has announced the start of an investigator-initiated trial in China for its autologous FasTCAR therapeutic candidate, GC012F, for the treatment of refractory systemic lupus erythematosus (SLE). GC012F is a CD19/BCMA dual-targeting CAR-T therapy that aims to deplete autoantibodies producing B-cells and plasma cells. SLE is a chronic autoimmune disease with limited treatment options and high unmet medical need. GC012F has shown strong efficacy and safety in hematological malignancies and this trial marks an important step in its development for autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.31%
Tags
none
-
Rhea-AI Summary
Gracell Biotechnologies Inc. (NASDAQ: GRCL) will participate in two upcoming investor conferences, the CICC Healthcare Industry Forum 2023 and the Shanghai Citi APAC Healthcare Conference 2023. The management team will attend one-on-one and group meetings at both conferences, which will take place on May 17, 2023, in Shanghai and May 18, 2023, in Hong Kong.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.98%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.52%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
none
Gracell Biotechnologies Inc

Nasdaq:GRCL

GRCL Rankings

GRCL Stock Data

989.87M
165.04M
16.39%
63.11%
1.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China
Suzhou

About GRCL

gracell biotechnologies inc. is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. leveraging its pioneering fastcar and truucar technology platforms, gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional car-t therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective car-t therapies for solid tumors.